Antidepressant and tolerance: Determinants and management of major side effects;Antidépresseurs et tolérance : déterminants et prise en charge des principaux effets indésirables

Encephale

Volumn 42, Issue 6, 2016, Pages 553-561

  David, D J ^a   Gourion, D ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b NONE   (France)

Author keywords

Antidepressant; Nausea vomiting; Sexual dysfunction; Side effects; Sleep disorders; Tolerance; Weight gain

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DOPAMINERGIC TRANSMISSION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; NAUSEA; PSYCHOPHARMACOTHERAPY; SEROTONINERGIC TRANSMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; VOMITING; WEIGHT CHANGE; COMPLICATION; DEPRESSIVE DISORDER;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84979547101     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2016.05.006     Document Type: Article

References (47)

1. [1] DALYs GBD, Collaborators H, Murray, C.J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
2. [2] Ferrari, A.J., Charlson, F.J., Norman, R.E., et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One, 8, 2013, e69637.
3. [3] Wong, M.L., Licinio, J., Research and treatment approaches to depression. Nat Rev Neurosci 2 (2001), 343–351.
4. [4] Trivedi, M.H., Rush, A.J., Wisniewski, S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Clin Psychiatry 163 (2006), 28–40.
5. [5] Fava, M., Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 61:Suppl. 2 (2000), 10–12.
6. [6] Lôo, H.G., Poirier, A., Hartmann, M.F.J.P., et al. Antidépresseurs. Historique. EMC-Psychiatrie, 1, 2004, 243–245.
7. [7] David, D.J., Gardier, A.M., The pharmacological basis of the serotonin system: application to antidepressant response. Encéphale, 2016, 10.1016/j.encep.2016.03.012.
8. [8] Llorca, P.A.N., Effets indésirables prévisibles du fait des propriétés pharmacologiques Corruble, E., (eds.) Les Antidépresseurs, 2013, Médecine Sciences Publications/Lavoisier, 219–228.
9. [9] Sternbach, H., The serotonin syndrome. Am J Psychiatry 148 (1991), 705–713.
10. [10] Trindade, E., Menon, D., Topfer, L.A., et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159 (1998), 1245–1252.
11. [11] Rosenzweig-Lipson, S., Beyer, C.E., Hughes, Z.A., et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113 (2007), 134–153.
12. [12] Licitsyna, O., Ansseau, M.W.P., Dysfonctions sexuelles et antidépresseurs. Rev Med Liege 66 (2011), 61–63.
13. [13] Spector, I.P., Carey, M.P., Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 19 (1990), 389–408.
14. [14] Baldwin, D.S., Foong, T., Antidepressant drugs and sexual dysfunction. Br J Psychiatry 202 (2013), 396–397.
15. [15] Montejo, A.L., Llorca, G., Izquierdo, J.A., et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62:Suppl. 3 (2001), 10–21.
16. [16] Ferguson, J.M., SSRI antidepressant medications: adverse effects and tolerability. J Clin Psychiatry 3 (2001), 22–27.
17. [17] Rosen, R.C., Lane, R.M., Menza, M., Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19 (1999), 67–85.
18. [18] Briki, M., Haffen, E., Sechter, D., et al. Effets sur la libido. Corruble, E., (eds.) Les Antidépresseurs, 2013, Médecine Sciences Publications/Lavoisier, 219–228.
19. [19] Graf, H., Walter, M., Metzger, C.D., et al. Antidepressant-related sexual dysfunction – perspectives from neuroimaging. Pharmacol Biochem Behav 121 (2014), 138–145.
20. [20] Stahl, S.M., Grady, M.M., Moret, C., et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 10 (2005), 732–747.
21. [21] Bijlsma, E.Y., Chan, J.S., Olivier, B., et al. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?. Pharmacol Biochem Behav 121 (2014), 88–101.
22. [22] Chan, J.S., Olivier, B., de Jong, T.R., et al. Translational research into sexual disorders: pharmacology and genomics. Eur J Pharmacol 585 (2008), 426–435.
23. [23] Miller, A.D., Leslie, R.A., The area postrema and vomiting. Front Neuroendocrinol 15 (1994), 301–320.
24. [24] McManis, P., Talley, N., Nausea and vomiting associated with selective serotonin reuptake inhibitors: incidence, mechanisms, and management. CNS Drugs 8 (1997), 394–401.
25. [25] Nutt, D., Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 391 (1997), 31–37.
26. [26] Navari, R.M., Aapro, M., Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New Engl J Med 374 (2016), 1356–1367.
27. [27] Bailey, J.E., Potokar, J., Coupland, N., et al. The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9 (1995), 137–141.
28. [28] Greist, J., McNamara, R.K., Mallinckrodt, C.H., et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 26 (2004), 1446–1455.
29. [29] Nihalani, N., Schwartz, T.L., Siddiqui, U.A., et al. Obesity and psychotropics. CNS Neurosci Ther 18 (2012), 57–63.
30. [30] Kivimaki, M., Hamer, M., Batty, G.D., et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 33 (2010), 2611–2616.
31. [31] Uguz, F., Sahingoz, M., Gungor, B., et al. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry 37 (2015), 46–48.
32. [32] Himmerich, H., Schuld, A., Haack, M., et al. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 38 (2004), 485–489.
33. [33] Wysokinski, A., Kloszewska, I., Mechanisms of increased appetite and weight gain induced by psychotropic medications. J Adv Clin Pharmacol 1 (2014), 12–33.
34. [34] De Vry, J., Schreiber, R., Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 24 (2000), 341–353.
35. [35] Wilson, S., Argyropoulos, S., Antidepressants and sleep: a qualitative review of the literature. Drugs 65 (2005), 927–947.
36. [36] Adrien, J., Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 6 (2002), 341–351.
37. [37] Stein, D.J., Lopez, A.G., Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther 28 (2011), 1021–1037.
38. [38] Brecht, S., Courtecuisse, C., Debieuvre, C., et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatr 68 (2007), 1707–1716.
39. [39] Mayers, A.G., Baldwin, D.S., Antidepressants and their effect on sleep. Hum Psychopharmacol 20 (2005), 533–559.
40. [40] Drago, A., SSRIs impact on sleep architecture: guidelines for clinician use. Clin Neuropsychiatry 5 (2008), 115–131.
41. 3 receptor in the dorsal raphe nucleus suppresses REM sleep in the rat. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008), 940–947.
42. 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 321 (2007), 690–698.
43. [43] Bonaventure, P., Dugovic, C., Kramer, M., et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 342 (2012), 429–440.
44. 7 receptor blockade on circadian rhythm regulation in rodents. Physiol Behav 110-111 (2013), 42–50.
45. [45] Goldberg, J.F., Ernst, C.L., Managing the side effects of psychotropic medications. American Psychiatric Publishing, 1st ed., 2012, American Psychiatric Pub, Washington, DC.
46. [46] Planes, S., Villier, C., Mallaret, M., The nocebo effect of drugs. Pharmacol Res Perspect, 4, 2016, e00208.
47. [47] Data-Franco, J., Berk, M., The nocebo effect: a clinicians guide. Aust N Z J Psychiatry 47 (2013), 617–623.